web analytics
5.7 C
Munich
Monday, October 18, 2021

Strategic Asset Leasing Inc., (OTCMKTS: LEAS) Powerful Runner as RM Candidate Looks To Go Pink Current and is Acquired by Dr. J Sinkule, CEO of PHARMIA, INC

Strategic Asset Leasing Inc., (OTCMKTS: LEAS) is making a major move northbound out of the triple zeroes to recent highs over a penny. The stock is quickly gaining traction among small cap investors and starting to attract some big players. Currently under heavy accumulation LEAS is looking to break out of its current trading range and blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; LEAS is on a blue-sky breakout well into copper land.  

LEAS has potential to be very big, currently trading at just a $10 million total market valuation the stock has a low float and a large following of investors that is growing very quickly. The Company is looking to go pink current with the Attorney’s letter filed on September 14 and was recently acquired by Dr. Joseph Sinkule, Co-Founder and CEO of PHARMIA focused on the production, marketing, and sales of life-saving drugs which are either “at risk” of being discontinued or in chronic short supply in the United States and Europe. Drugs referred to as “at risk” are those that are not considered highly profitable by the leading pharmaceutical manufacturers’ but are still essential in the treatment of life-threatening diseases. In this latter respect, PHARMIA is primarily focused on a portfolio of products to treat cancer and infectious diseases, and shortages of drugs caused by the coronavirus pandemic. Dr. Sinkule has over 35 years of drug, biologic, and medical device commercialization experience, and this serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics.  

Strategic Asset Leasing Inc., (OTCMKTS: LEAS) is a perfect merger candidate with a clean balance sheet and fairly low float. Microcapdaily reported on LEAS back in 2019 stating at that time on the Company: “Strategic Asset Leasing used to describe itself as a Company that helps businesses and non-profit organizations of all types and sizes throughout Canada and the United States acquire the equipment they need to operate and grow. The Company’s experienced team offers a full array of equipment financing structures and programs for any type of business. 

PHARMIA is focused on the production, marketing, and sales of life-saving drugs which are either “at risk” of being discontinued or in chronic short supply in the United States and Europe. Drugs referred to as “at risk” are those that are not considered highly profitable by the leading pharmaceutical manufacturers’ but are still essential in the treatment of life-threatening diseases. In this latter respect, PHARMIA is primarily focused on a portfolio of products to treat cancer and infectious diseases, and shortages of drugs caused by the coronavirus pandemic. 

To Find out the inside Scoop on LEAS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

LEAS

Almost 8 in 10 prescriptions filled in the U.S. are for generic drugs. Generic drugs are chemically identical to branded drugs and must meet the same strict standards in order to receive approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA). Generic drugs cost substantially less than brand name drugs because the manufacturer isn’t required to repeat costly animal and clinical research on ingredients or dosage forms that are already FDA approved for safety and effectiveness. Most people believe that if something costs more, it has to be better quality. In the case of generic drugs, this is not true. The standards for quality are exactly the same for brand name and generic products. PHARMIA puts quality at the forefront of its operations. Healthcare professionals and consumers can be assured that our drugs meet the same standards as branded drugs. 

According to LEAS filings Mammoth Energy Group, Inc. (A Development Stage Company) was incorporated on February 27, 2006 under the laws of the State of Nevada. Prior to its incorporation in Nevada, the Company had been incorporated as Technigen Corporation in Canada. It has had limited operations since its incorporation in the United States. In accordance with Accounting Standards Codification (“ASC”) 915, Development Stage Entities, the Company is considered to be in the development stage. In March of 2013, management decided to change jurisdiction to Wyoming, and to subsequently dissolve the Nevada Corporation. Mammoth Energy Group, Inc. was incorporated in Wyoming by filing Articles of Continuance on March 5, 2013. 

We also reported on LEAS in September 2020 after new CEO Jason Tucker acquired the company from its previous management in February bringing with him valuable Intellectual Property stating: “The Company is developing its flagship Cash App which supports real time tap-2-pay. Stategic has also entered the booming cannabis technology market, is developing 2 i.o.T products including the ‘Safe and Secure Nightlight’ (SSN). Integrated with WIFI, night light, motion sensor, beeper/alarm as well as an indoor air quality control system which connects to the homes furnace filter and link the user through a stand-alone app or integrated into other smart home systems such as Alexa, Nest or Google Home. Strategic also just signed an LOI to acquire a cryptocurrency mining data center including the building, infrastructure, and all mining hardware. The New Jersey based facility is Telecom Industry (ANSI/TIA-942) rated level 2, which exceeds the project’s demands and offers robust protection from physical events.” 

https://twitter.com/JustJessTrading/status/1445036721997946886

For More on LEAS Subscribe Right Now!

LEAS is making a major move northbound out of the triple zeroes to recent highs over a penny. The stock is quickly gaining traction among small cap investors and starting to attract some big players. Currently under heavy accumulation LEAS is looking to break out of its current trading range and blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; LEAS is on a blue-sky breakout well into copper land. LEAS has potential to be very big, currently trading at just a $10 million total market valuation the stock has a low float and a large following of investors that is growing very quickly. The Company is looking to go pink current with the Attorney’s letter filed on September 14 and was recently acquired by Dr. Joseph Sinkule, Co-Founder and CEO of PHARMIA focused on the production, marketing, and sales of life-saving drugs which are either “at risk” of being discontinued or in chronic short supply in the United States and Europe. Drugs referred to as “at risk” are those that are not considered highly profitable by the leading pharmaceutical manufacturers’ but are still essential in the treatment of life-threatening diseases. In this latter respect, PHARMIA is primarily focused on a portfolio of products to treat cancer and infectious diseases, and shortages of drugs caused by the coronavirus pandemic. Dr. Sinkule has over 35 years of drug, biologic, and medical device commercialization experience, and this serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. We will be updating on LEAS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with LEAS.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in LEAS either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.